Sepsis, defined as an extremely complex syndrome induced by infection, is a major public health concern according to the data of incidence, mortality and hospital costs reported. It remains a major cause of human disability and death throughout the world: it affects 30 million people worldwide every year (25% of sepsis patients die) and is the largest killer of children (around 82.000 every day; a death every three to four seconds). Accurate and early detection of sepsis remains a challenge.
Through the IVD4Sepsis project, Mecwins’ main objective is to bring to the market its proprietary AVAC technology as a reference technology for the detection of cytokine biomarkers, first for early sepsis diagnosis but with the ambition of later positioning it as the reference technology for a wide range of other clinical applications. IVD4Sepsis project will contribute to improve Sepsis diagnosis and therefore the survival rate of patients.
At the end of the project, IVD4Sepsis technology will meet the requirements of the sector and Mecwins will have the manufacturing capacity to cover the initial market penetration, creating important competitive technological and market advantages over future competitors, becoming a worldwide referent in offering analytical solutions in the diagnostic sector, first in the specific field of sepsis, but later extended to other critical illness fields such as oncology, cardiovascular diseases, autoimmune diseases and other infectious diseases than sepsis, such as HIV, meningitis.
